Vivos Therapeutics, Inc.(VVOS)

$0.14—

WatchlistAsk SA Chart

Vivos Therapeutics, Inc.(VVOS)

NASDAQ

$0.14—

WatchlistAsk SA Chart Studio

VVOS(VVOS)

VVOS

9/26/26

Vivos Therapeutics (VVOS)

Saturday

5:45 AM

ThesisThe recent partnership with a dental chain and positive clinical outcomes are shifting investor sentiment towards growth potential.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$17M	$24M	$39M
Rev. Growth	+16.0%	+36.8%	+63.0%
EPS	$-2.06	$-1.02	$-0.15
EPS Growth	+7.2%	+50.2%	+85.4%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $39M — +63.0% growth in a single year.

Why Revenue Could Explode

01Vivos has secured a new partnership with a major dental chain, expected to increase unit sales by 40% over the next year.
02Recent studies show a 25% improvement in patient outcomes with Vivos devices compared to traditional CPAP, potentially driving demand.
03Pending FDA approval for a new version of its oral appliance could significantly expand the addressable market.
04Growing awareness of sleep disorders and the need for effective treatments
05Shift towards non-invasive medical devices in healthcare
06Regulatory approvals for new products or enhancements
07Partnerships with dental practices and healthcare providers
08Market penetration rates in the OSA treatment segment

FY2025 Snapshot

Revenue: $17M
Rev. Growth: +16.0%
Gross Margin: 60.4%
Op. Margin: -114%
Net Margin: -122%
Net Income: $-21M
NI Growth: -90.6%
EPS: $-2.06
1Y Return: -96.0%

VVOS Chart

My Notes

"Our innovative approach is gaining traction, and we are excited about the future of sleep apnea treatment."
Moat: Vivos' patented technology provides a unique solution that differentiates it from traditional CPAP devices.
growth - Investors looking for innovative healthcare solutions with potential for high returns.
Minimal impact as the company does not rely heavily on debt financing; however…
Watch on earnings: Regulatory approval timelines for new products, Market share in the OSA treatment market, Patient compliance rates with Vivos devices.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $24M to $39M as vivos has secured a new partnership with a major dental chain, expected to increase unit sales by 40% over the next year.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

—

Why Revenue Could Explode

01Vivos has secured a new partnership with a major dental chain, expected to increase unit sales by 40% over the next year.

02Recent studies show a 25% improvement in patient outcomes with Vivos devices compared to traditional CPAP, potentially driving demand.

03Pending FDA approval for a new version of its oral appliance could significantly expand the addressable market.

04Growing awareness of sleep disorders and the need for effective treatments

05Shift towards non-invasive medical devices in healthcare

06Regulatory approvals for new products or enhancements

07Partnerships with dental practices and healthcare providers

08Market penetration rates in the OSA treatment segment

My Notes

"Our innovative approach is gaining traction, and we are excited about the future of sleep apnea treatment."

Moat: Vivos' patented technology provides a unique solution that differentiates it from traditional CPAP devices.

growth - Investors looking for innovative healthcare solutions with potential for high returns.

Minimal impact as the company does not rely heavily on debt financing; however…

Watch on earnings: Regulatory approval timelines for new products, Market share in the OSA treatment market, Patient compliance rates with Vivos devices.